Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis” Moon Haeng Hur, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(1): e93. CrossRef
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Ramanpreet Singh, Mina S. Makary Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: An Inverse Probability of Treatment Weighted Analysis Jihoon Kim, Jin-Hyoung Kim, Byung Soo Im, Gun Ha Kim, Hee Ho Chu, Dong Il Gwon, Ji Hoon Shin, Ju Hyun Shim, Sang Min Yoon, Sehee Kim Cancers.2025; 18(1): 33. CrossRef
Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim
Clin Mol Hepatol 2023;29(3):763-778. Published online May 30, 2023
Background/Aims Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine kinase inhibitor (TKI) in patients with HCC and PVTT remains unclear. We compared the outcomes of TARE and TKI therapy in treatment-naïve patients with locally advanced HCC and segmental or lobar PVTT.
Methods This multicenter study included 216 patients initially treated with TARE (n=124) or TKI (sorafenib or lenvatinib; n=92) between 2011 and 2021. Baseline characteristics were balanced using propensity score matching (PSM) or inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS). The secondary outcomes included progression-free survival (PFS) and objective response rate (ORR).
Results In the unmatched cohort, the median OS of the TARE and TKI groups were 28.2 and 7.2 months, respectively (p<0.001), and the TARE group experienced significantly and independently longer OS compared to the TKI group (adjusted hazard ratio=0.41, 95% confidence interval=0.28–0.60, p<0.001). Similar results were observed in the study cohorts balanced with IPTW (p=0.003) or PSM (p=0.004). Although PFS was comparable between the two groups, the TARE group showed a trend of prolonged PFS in a subpopulation of patients with Vp1 or Vp2 PVTT (p=0.052). In the matched cohorts, the ORR of the TARE group was 53.0–56.7%, whereas that of the TKI group was 12.3–15.0%.
Conclusions For patients with advanced HCC with segmental or lobar PVTT and well-preserved liver function, TARE may provide superior OS compared to sorafenib or lenvatinib.
Citations
Citations to this article as recorded by
Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis Youngsu Park, Yuri Cho, Seung Up Kim, Aryoung Kim, Hyunjae Shin, Hyo-Cheol Kim, In Joon Lee, Gyoung Min Kim, Dongho Hyun, Yunmi Ko, Jeayeon Park, Jae Woong Yoon, Gyung Sun Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Diagnostic and Interventional Imaging.2026; 107(1): 25. CrossRef
Transarterial radioembolization challenges immunotherapy as first-line care for hepatocellular carcinoma with portal vein tumor thrombosis Anna Pellat, Maxime Barat Diagnostic and Interventional Imaging.2026; 107(1): 1. CrossRef
Progress in hepatoprotective strategies during TACE treatment Chenlu Qian, Yan Wu, Chuan Yin, Jie Gao Advanced Interventional Materials.2026; 1(1): 100012. CrossRef
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Ramanpreet Singh, Mina S. Makary Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Pre-transplant downstaging strategies for hepatocellular carcinoma with portal vein tumor thrombus: Current therapies and future challenges Zong-Yang Li, Cheng Xie, Hong-Qiao Cai World Journal of Hepatology.2025;[Epub] CrossRef
Radioembolization in Hepatocellular Carcinoma: Indications and Outcomes Bahareh Gholami, Ali Afrasiabi, Paolo Varela, Samira Gholami, Andrew Moon, Alexander Villalobos, David Mauro, Bryan Harris, Hyeon Yu, Nima Kokabi Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy Licong Liang, Yuchan Liang, Wensou Huang, Yongjian Guo, Jingjun Huang, Jingwen Zhou, Liteng Lin, Xinxin Nie, Mingyue Cai, Kangshun Zhu Liver Research.2025;[Epub] CrossRef
Radio-magnetic dual-functional microspheres for magnetic hyperthermia therapy combined with radioembolization of hepatocellular carcinoma Manran Wu, Dong Wang, Yu Qin, Xunhao Qi, Qian Huang, Xingwei Sun, Yong Jin, Ran Zhu, Guanglin Wang, Pengfei Rong Materials Today Bio.2025; 35: 102553. CrossRef
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park JHEP Reports.2024; 6(4): 100991. CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022 Yuri Cho, Bo Hyun Kim, Young-Suk Lim Digestive Disease Interventions.2024; 08(03): 169. CrossRef
Research Progress in Predicting Hepatocellular Carcinoma with Portal Vein Tumour Thrombus in the Era of Artificial Intelligence Yaduo Li, Ningning Fan, Xu He, Jianjun Zhu, Jie Zhang, Ligong Lu Journal of Hepatocellular Carcinoma.2024; Volume 11: 1429. CrossRef
Liver transplantation following two conversions in a patient with huge hepatocellular carcinoma and portal vein invasion: A case report Li-Cong Liang, Wen-Sou Huang, Zhao-Xiong Guo, Hong-Ji You, Yong-Jian Guo, Ming-Yue Cai, Li-Teng Lin, Guo-Ying Wang, Kang-Shun Zhu World Journal of Gastroenterology.2024; 30(36): 4071. CrossRef
Transarterial intervention therapy combined with systemic therapy for HCC: a review of recent five-year articles Chao Fu, Hongsen Chen, Yifan Chen, Wenbin Liu, Guangwen Cao Hepatoma Research.2024;[Epub] CrossRef
The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation Kaina Chen, Aaron K.T. Tong, Fiona N.N. Moe, David C.E. Ng, Richard H.G. Lo, Apoorva Gogna, Sean X. Yan, Sue Ping Thang, Kelvin S.H. Loke, Nanda Karaddi Venkatanarasimha, Hian Liang Huang, Chow Wei Too, Timothy S.K. Ong, Eng Xuan Yeo, Daniel Yang Yao Peh, Liver Cancer.2024; : 1. CrossRef
Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein throm Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon Clinical and Molecular Hepatology.2024; 30(4): 659. CrossRef
Unexpected Anti-tumor Effect of Selective Internal Radiation Therapy and Radiofrequency Ablation Followed by Immune Checkpoint Inhibitors for Hepatocellular Carcinoma Mingzhi Hao, Hai Lan Lin, Yubin Hu, Qizhong Chen, Zhangxian Chen, Linbin Qiu, Duanyu Lin, Hui Zhang, Zuting Fang, Jingfeng Liu Hepatitis Monthly.2024;[Epub] CrossRef
Transarterial radioembolization (TARE) with yttrium 90 (90Y), an intra-arterial procedure performed by interventional radiologists, has begun being utilized in managing hepatocellular carcinoma (HCC) in Korea. There are two available TARE products: glass and resin microspheres with different physical characteristics. All patients undergoing TARE must be assessed with clinical examination and laboratory tests as well as a thorough angiographic evaluation. TARE is safe and effective in the treatment of unresectable HCC, as it has longer time-to-progression, greater ability to downsize tumors for liver transplantation, less post-embolization syndrome, and shorter hospitalization compared with chemoembolization. TARE can also serve as an alternative to ablation, surgical resection, portal vein embolization, and sorafenib. The utility of TARE continues to expand with new insights in interventional oncology.
Citations
Citations to this article as recorded by
The Role of TARE for Bridging and Downstaging of HCC Before Resection or Liver Transplant Abdullah Alshamrani, Sung Ki Cho, Namkee Oh, Jinsoo Rhu, Gyu-Seong Choi, Dong-Ho Hyun, Jongman Kim Cancers.2026; 18(2): 225. CrossRef
Turning Waste into Treasure: Radiation Byproduct-Induced Fe(III)/Fe(II) Conversion for Efficient Ferroptosis to Improve Iodine-131-Based Transarterial Radioembolization for Liver Tumors Jiangnan Xu, Xiu Luo, Weiwei Su, Guorong Jia, Huawei Cai, Danni Li, Rou Li, Xiangdong Wang, Yefa Yang, Tao Wang, Changjing Zuo ACS Applied Materials & Interfaces.2025; 17(20): 29170. CrossRef
Complications of transarterial radioembolization in hepatic malignancies: Pathophysiological insights and management paradigms Mengdi Qi, Zijia Tao, Duo Yu, Yang Zuo, Hongshan Zhong European Journal of Radiology.2025; 190: 112224. CrossRef
Temporal evolution of the LI-RADS radiation treatment response assessment on multiphase CT/MRI in patients undergoing selective internal radiation therapy for hepatocellular carcinoma Hong Wei, Hanyu Jiang, Jeongin Yoo, Jae Hyun Kim, Hyo-Jin Kang, Yuanan Wu, Rongbo Liu, Hyo-Cheol Kim, Jeong Min Lee European Radiology.2025; 35(11): 7349. CrossRef
Microporous 3D bioprinting: a novel technology for biofabrication Hongxiang Cai, Yongrui Cai, Zichuan Ding, Jiaxuan Fan, Yahao Lai, Chao Huang, Boyi Jiang, Can Zhou, Zongke Zhou, Xingcai Zhang, Zeyu Luo Bio-Design and Manufacturing.2025; 8(5): 847. CrossRef
Assessment of Preprocedural Factors Associated with 5-Year Complete Response After Transarterial Radioembolization in Patients with Hepatocellular Carcinoma June Park, Dong Kyu Kim, Seungsoo Lee, Shin Hye Hwang Diagnostics.2025; 15(18): 2297. CrossRef
Radioembolization for hepatocellular carcinoma Yoselin Dos Santos Poleo, Abrahams Ocanto Martínez Revisiones en Cáncer.2025;[Epub] CrossRef
Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies Xuexiao Li, Binyan Zhong, Nan Jiang, Jintao Huang, Di Hu, Ruoran Zhou, Jianfeng Zeng, Wenmiao Shu, Guangxin Duan, Shuwang Wu, Ling Wen Journal of Advanced Research.2025;[Epub] CrossRef
Overcoming drug resistance microspheres combined with photothermal ablation reinforce transcatheter arterial chemoembolization of hepatocellular carcinoma Jiheng Shan, Chengzhi Zhang, Yiming Liu, Bingtong Yue, Bin Han, Jing Li, Guodun Zheng, Kunpeng Wu, Huijuan Wu, Yiran Wang, Qingqing He, Xiaonan Shan, Zongming Li, Ping Wu, Kewei Ren, Zhen Li, Jianzhuang Ren, Linyong Du, Yanan Zhao, Xinwei Han Communications Materials.2025;[Epub] CrossRef
PET/CT and SPECT/CT imaging of 90Y hepatic radioembolization at therapeutic and diagnostic activity levels: Anthropomorphic phantom study Anna Budzyńska, Agata Kubik, Krzysztof Kacperski, Patrycja Pastusiak, Michał Kuć, Piotr Piasecki, Marcin Konior, Michał Gryziński, Mirosław Dziuk, Edward Iller, Alexander Hohn PLOS ONE.2024; 19(2): e0271711. CrossRef
Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment Fei Feng, Yue Zhao Medical Principles and Practice.2024; 33(5): 414. CrossRef
Amidoxime-based radio-microspheres for Internal Irradiation combined with a checkpoint-blocking nanobody boost antitumor immunity Zhenwen Zhao, Yulun Chen, Hui Liu, Haitian Tang, Minglei Teng, Xue Liu, Jianlin Ge, Shilong Shao, Zhenjie Li, Tao Jiang, Chao Liu, Xiao Xu, Gang Liu Nano Today.2024; 57: 102383. CrossRef
Radioembolization for hepatocellular carcinoma: updated strategies and evolving clinical applications Jirapa Chansangrat, Sameer Gadani Hepatoma Research.2024;[Epub] CrossRef
3D Hollow Porous Radio‐Granular Hydrogels for SPECT Imaging‐Guided Cancer Intravascular Brachytherapy Xiao Xu, Hu Chen, Pan He, Zhenwen Zhao, Xing Gao, Chao Liu, Hongwei Cheng, Lai Jiang, Peiyu Wang, Yang Zhang, Xiaofei Wen, Yesen Li, Jinxiong Huang, Yongfu Xiong, Jingsong Mao, Hongjuan Ma, Gang Liu Advanced Functional Materials.2023;[Epub] CrossRef
Microspheres as a Carrier System for Therapeutic Embolization Procedures: Achievements and Advances Mick. M. Welling, Nikolas Duszenko, Maarten P. van Meerbeek, Tom J. M. Molenaar, Tessa Buckle, Fijs W. B. van Leeuwen, Daphne D. D. Rietbergen Journal of Clinical Medicine.2023; 12(3): 918. CrossRef
Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients Sung Won Chung, Heejin Cho, Hyunjae Shin, Jeayeon Park, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Myungsu Lee, Yoon Jun Kim, Jin Chul Paeng, Jung-Hwan Yoon, Jin Wook Chung, Jeong-Hoon Lee, Hyo-Cheol Kim Frontiers in Oncology.2023;[Epub] CrossRef
Post-embolization Syndrome Following Yttrium-90 Radiation Segmentectomy Naisarg B Vanani, Abhishek Janardan, Nisar Asmi, Pinky Jha Cureus.2023;[Epub] CrossRef
Radio-granular hydrogels for image-guided tumor brachytherapy Shilong Shao, Xiao Xu, Gan Lin, Gang Liu iLIVER.2023; 2(3): 177. CrossRef
A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC Joon Yeul Nam, Yun Bin Lee, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Wook Chung, Jung-Hwan Yoon, Yoon Jun Kim Digestive Diseases and Sciences.2022; 67(1): 329. CrossRef
Facile preparation of 177Lu-microspheres for hepatocellular carcinoma radioisotope therapy Manran Wu, Kexin Shi, Ruizhe Huang, Chunyi Liu, Lingling Yin, Weipeng Yong, Jing Sun, Guanglin Wang, Zhiyuan Zhong, Mingyuan Gao Chinese Chemical Letters.2022; 33(7): 3492. CrossRef
Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients Sun Young Yim, Ho Soo Chun, Jae Seung Lee, Ji-Hwan Lim, Tae Hyung Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Gyoung Min Kim, Jong Yun Won, Yeon Seok Seo, Yun Hwan Kim, Soon Ho Um, Do Young Kim Cancers.2022; 14(2): 385. CrossRef
Development of neutron-activated samarium-153-loaded polystyrene microspheres as a potential theranostic agent for hepatic radioembolization Hun Yee Tan, Yin How Wong, Azahari Kasbollah, Mohammad Nazri Md Shah, Basri Johan Jeet Abdullah, Alan Christopher Perkins, Chai Hong Yeong Nuclear Medicine Communications.2022; 43(4): 410. CrossRef
Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma Shaohua Li, Min Deng, Qiaoxuan Wang, Jie Mei, Jingwen Zou, Wenping Lin, Ming Shi, Minshan Chen, Wei Wei, Rongping Guo, Bruno Vincenzi Journal of Oncology.2022; 2022: 1. CrossRef
Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study Eleni Gkika, Anca-Ligia Grosu, Teresa Macarulla Mercade, Antonio Cubillo Gracián, Thomas B. Brunner, Michael Schultheiß, Monika Pazgan-Simon, Thomas Seufferlein, Yann Touchefeu Cancers.2022; 14(6): 1568. CrossRef
Radioembolization for hepatocellular carcinoma: what clinicians need to know Jin Woo Choi, Hyo-Cheol Kim Journal of Liver Cancer.2022; 22(1): 4. CrossRef
Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality Therapy Qianyi Lin, Dexiong Chen, Kangde Li, Xiaomin Fan, Qi Cai, Weihong Lin, Chunhong Qin, Tao He Frontiers in Radiology.2022;[Epub] CrossRef
Association of dysmorphic intratumoral vessel with high lung shunt fraction in patients with hepatocellular carcinoma Tae Won Choi, Ijin Joo, Hyo-Cheol Kim Scientific Reports.2022;[Epub] CrossRef
Radiochemical Feasibility of Mixing of 99mTc-MAA and 90Y-Microspheres with Omnipaque Contrast Chang-Tong Yang, Pei Ing Ngam, Vanessa Jing Xin Phua, Sidney Wing Kwong Yu, Gogna Apoorva, David Chee Eng Ng, Hian Liang Huang Molecules.2022; 27(21): 7646. CrossRef
Theranostic approach in liver cancer: an emerging paradigm to optimize personalized medicine Narges Jokar, Farzad Moradhaseli, Hojjat Ahmadzadehfar, Esmail Jafari, Saman Nikeghbalian, Ali Reza Rasekhi, Majid Assadi Clinical and Translational Imaging.2022; 11(1): 51. CrossRef
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study Dong Hyun Sinn, Hye Won Lee, Yong-Han Paik, Do Young Kim, Yoon Jun Kim, Kang Mo Kim, Si Hyun Bae, Ji Hoon Kim, Yeon Seok Seo, Jae Young Jang, Byoung Kuk Jang, Hyung Joon Yim, Hyung Joon Kim, Byung Seok Lee, Bo Hyun Kim, In Hee Kim, Eun-Young Cho, Jung Il Digestive Diseases and Sciences.2021; 66(1): 315. CrossRef
Highly Tumor-Specific and Long-Acting Iodine-131 Microbeads for Enhanced Treatment of Hepatocellular Carcinoma with Low-Dose Radio-Chemoembolization Yuyi Qian, Qiufang Liu, Panli Li, Yaobao Han, Jianping Zhang, Jiaojiao Xu, Jingwen Sun, Aihua Wu, Shaoli Song, Wei Lu ACS Nano.2021; 15(2): 2933. CrossRef
Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention Joseph H. Yacoub, David Mauro, Andrew Moon, Aiwu R. He, Mustafa R. Bashir, Christine C. Hsu, Thomas M. Fishbein, Lauren M. B. Burke Abdominal Radiology.2021; 46(8): 3540. CrossRef
LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma Jongjin Yoon, Sunyoung Lee, Jaeseung Shin, Seung-seob Kim, Gyoung Min Kim, Jong Yun Won Korean Journal of Radiology.2021; 22(8): 1279. CrossRef
Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Current Oncology.2021; 28(1): 965. CrossRef
Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study Minseok Albert Kim, Heejoon Jang, Na Ryung Choi, Joon Yeul Nam, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Wook Chung, Jung-Hwan Yoon, Yoon Jun Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 1565. CrossRef
Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma Melissa Borgia, Michele Dal Bo, Giuseppe Toffoli Cancers.2021; 13(17): 4387. CrossRef
Antitumor Effects of Triterpenes in Hepatocellular Carcinoma Antoni Sureda, Miquel Martorell, Xavier Capó, Margalida Monserrat-Mesquida, Maria Magdalena Quetglas-Llabrés, Mahsa Rasekhian, Seyed M. Nabavi, Silvia Tejada Current Medicinal Chemistry.2021; 28(13): 2465. CrossRef
Preparation and characterization of inorganic radioactive holmium-166 microspheres for internal radionuclide therapy A.G. Arranja, W.E. Hennink, C. Chassagne, A.G. Denkova, J.F.W. Nijsen Materials Science and Engineering: C.2020; 106: 110244. CrossRef
Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization Jae Seung Lee, Han Ah Lee, Mi Young Jeon, Tae Seop Lim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Soon Ho Um, Kwang-Hyub Han, Yeon Seok Seo, Seung Up Kim European Journal of Gastroenterology & Hepatology.2020; 32(6): 739. CrossRef
Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis Richard F Pollock, Victoria K Brennan, Ralph Peters, Philipp M Paprottka Expert Review of Anticancer Therapy.2020; 20(11): 997. CrossRef
The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization Jae Seung Lee, Hong Jun Choi, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Song-Ee Baek, Yong Eun Chung, Mi-Suk Park, Myeong-Jin Kim, Hyungjin Rhee, Seung Up Kim Gut and Liver.2020; 14(6): 765. CrossRef
Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage Alberta Cappelli, Paloma Sangro, Cristina Mosconi, Iris Deppe, Eleonora Terzi, Jose I. Bilbao, Macarena Rodriguez-Fraile, Caterina De Benedittis, Jens Ricke, Rita Golfieri, Bruno Sangro European Journal of Nuclear Medicine and Molecular Imaging.2019; 46(3): 661. CrossRef
Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm Hyo-Cheol Kim, Yoon Jun Kim, Jeong-Hoon Lee, Kyung-Suk Suh, Jin Wook Chung Journal of Vascular and Interventional Radiology.2019; 30(1): 1. CrossRef
Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors Juan C. Spina, Isabel Hume, Ana Pelaez, Oscar Peralta, Marcos Quadrelli, Ricardo Garcia Monaco RadioGraphics.2019; 39(2): 578. CrossRef
Designing pH-triggered drug release iron oxide nanocomposites for MRI-guided photothermal-chemoembolization therapy of liver orthotopic cancer Fengyong Liu, Xin Li, Yangyang Li, Yuchen Qi, Hongjun Yuan, Jian He, Wanlin Li, Min Zhou Biomaterials Science.2019; 7(5): 1842. CrossRef
Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System Sonal Krishan, Radha K. Dhiman, Navin Kalra, Raju Sharma, Sanjay S. Baijal, Anil Arora, Ajay Gulati, Anu Eapan, Ashish Verma, Shyam Keshava, Amar Mukund, S. Deva, Ravi Chaudhary, Karthick Ganesan, Sunil Taneja, Ujjwal Gorsi, Shivanand Gamanagatti, Kumble Journal of Clinical and Experimental Hepatology.2019; 9(5): 625. CrossRef
Intravoxel Incoherent Motion Parameters for Assessing the Efficiency of Locoregional Bridging Treatments before Liver Transplantation Sadık Server, Soheil Sabet, Refik Bilgin, Nagihan Inan, Yıldıray Yuzer, Yaman Tokat Transplantation Proceedings.2019; 51(7): 2391. CrossRef
Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know Ijin Joo, Hyo-Cheol Kim, Gyoung Min Kim, Jin Chul Paeng Korean Journal of Radiology.2018; 19(2): 209. CrossRef
Yttrium-90 Radioembolization of the Right Inferior Phrenic Artery in 20 Patients with Hepatocellular Carcinoma Hyo-Cheol Kim, Yoon Jun Kim, Jin Chul Paeng, Jin Wook Chung Journal of Vascular and Interventional Radiology.2018; 29(4): 556. CrossRef
Treatment of Hepatocellular Carcinoma: A Cost Analysis Of Yttrium-90 Transarterial Radioembolization Versus Sorafenib Maria Grazia Lucà, Roberto Nani, Melanie Schranz, Massimo De Giorgio, Claudia Iegri, Roberto Agazzi, Francesco Sala, Giorgio Virotta, Donatella Sarti, Grazia Conte, Domenico Pinelli, Carlo Nicora, Michele Colledan, Sandro Sironi, Stefano Fagiuoli Future Oncology.2018; 14(8): 727. CrossRef
Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor Song Yi Lee, Jin Woo Choi, Jae-Young Lee, Dae-Duk Kim, Hyo-Cheol Kim, Hyun-Jong Cho Drug Delivery.2018; 25(1): 1472. CrossRef
Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy Aldona Kasprzak, Agnieszka Adamek International Journal of Molecular Sciences.2018; 19(12): 3887. CrossRef
First
Prev
